Millions of Americans report that they are unable to fill their prescriptions or are not taking their medications as prescribed because they cannot afford them, generating bipartisan interest in ...
While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. Since ...
Abeona Therapeutics Inc. announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million, following FDA approval of its treatment ZEVASKYN™. This sale is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback